Study confirms HORIBA’s Microsemi CRP POCT aids urgent care decision making in GP practice through combined FBC & CRP

Northampton, UK – 14th December 2020 – HORIBA UK Ltd, Medical announces that Oxford Academic Health Science Network (AHSN) has recently published a study exploring use of point-of-care testing (POCT) within a busy GP group practice [1]. The study, using HORIBA Medical’s novel Microsemi CRP POC haematology analyser, aimed to relieve winter flu pressures and to meet local Clinical Commissioning Group (CCG) demands to reduce unnecessary hospital visits and admissions. Its results demonstrate tangible benefits for urgent care clinical decision making and cost savings by using this POC technology in primary care. The current pressures on health services due to COVID-19 also render the findings very relevant.

The Brookside Group Practice (Lower Earley, Berkshire) had previously introduced a new patient pathway model by creating a multidisciplinary, paramedic-led urgent care clinic, aiming to retain patients in a primary care setting where possible. Already the subject of an in-depth audit and evaluation working alongside the AHSN, the practice’s urgent care model was shown to deliver reduced waiting times, more efficient referrals, and cost savings of between 4% to 38% [1]. The introduction of pathology POCT represented the second phase of the project to further enhance their decision-making process.

Previous studies have also highlighted the benefits of using Microsemi CRP POCT in urgent care pathways to enable more rapid clinical decision-making, saving time and reducing costs, and thereby improve clinical service delivery [2]. This instrument was therefore selected for use at the Brookside urgent care unit.

The Microsemi CRP requires just 18 µL of whole blood to deliver the simultaneous measurement of full blood count (FBC), including three-part differential, and C-Reactive Protein (CRP) within four minutes. The combination of CRP, an inflammatory marker, and white blood count plus granulocyte count, helps to identify sepsis, distinguish between bacterial and viral infection and also establishes the severity of disease. To offer a full suite of POCT measurements, this analyser was placed alongside the i-STAT Alinity (Abbott) which detects blood chemistry abnormalities.

Following training, the analysers were operated by a variety of clinical staff: GPs, nursing staff and paramedics, demonstrating the ease with which the instrumentation can be operated. The study confirmed that the introduction of POCT at the GP practice fully supported the clinical decision-making process for a range of urgent care needs. It increased clinical confidence in diagnosis within the urgent care clinic leading to more appropriate patient referrals to secondary care. Indicative modelling on the costs of testing and secondary care referrals against instances where referrals were avoided established potential cost savings of over £26,000 annually.

Feedback from healthcare professionals involved in the study also confirmed that the availability of a POC test result allowed them to have a more meaningful or specific discussion with the patient about their diagnosis. Furthermore, patients tended to accept a test result more readily than the clinical opinion of the medical professional alone. Therefore, this POCT also served to improve patient experience and outcomes.

The Microsemi CRP analyser has been installed across a variety of primary and secondary care settings, including community hubs, emergency departments and assessment units where it is operated by multidisciplinary healthcare teams. In addition, CRP testing has been demonstrated to be a useful indicator of severity for COVID-19 patients [3] alongside the more general application of the instrument’s parameters in patient triage. 

“The current COVID-19 pandemic has provided a catalyst to explore different models for delivering care efficiently. This and studies like the one produced by Oxford AHSN have the potential to help shape the future of primary care,” commented Cleve Wright, Director, HORIBA Medical UK. “Our Microsemi CRP has been shown to be an invaluable POCT tool to support clinical decision making for urgent care pathways in primary care settings.” 

The full study is available at: https://www.oxfordahsn.org/wp-content/uploads/2020/11/Use-of-POC-testing-in-a-GP-Urgent-Care-Pathway-Report-Final-22-10-20.pdf

1.    Checketts G, Okhai N, Bajre M, Sharma A, Edwards A, Hart J. Introducing point of care (POC) testing in a primary care urgent care pathway to improve clinical service delivery. Oxford Academic Health Science Network (2020)
2.    McDonald C, Philpott J, Segal S, Hart J. Can using point of care blood tests in emergency paediatric units improve quality of care? Oxford Academic Health Science Network (2017)
3.    Siatka C, Eveillard M, Nishimura J, Duroux C, Ferrandi G. COVID-19 screening, prognosis and severity assessment with biomarkers for management of patients. HORIBA Medical White Paper. Published 10 April 2020

This press release is available online at: https://www.horiba.com/uk/medical/news-events/news/article/study-confirms-horibas-microsemi-crp-poct-aids-urgent-care-decision-making-in-gp-practice-through-combined-fbc-and-crp-67539/


EKF signs DiaSpect Tm U.S. distribution agreement with McKesson to launch McKesson Consult® Hb analyzer

FDA cleared POC hemoglobin analyzer to be sold across the USA by the market’s leading and most esta...

Read More >


A new exhibition at the Science Museum, London will feature an invention from the Oxford area which ...

Read More >

DiaSorin and Tecan to collaborate in new platform development

DiaSorin and Tecan Group have announced that they have agreed to collaborate in a development under ...

Read More >

MBM and OCB launch ColoProg in China on March 7th 2018

Oxford developed prognostic assay for risk of post-surgical recurrence in Stage II colorectal cance...

Read More >

BBI Solutions Increases Capacity for Cell Culture Native Human Transferrin Production

BBI Solutions (BBI) has invested into its facilities and resource in order to increase the capacity ...

Read More >

Cytox in Collaboration with AKESOgen Extends Genetic Test for Assessing Alzheimer's Disease

8th May 2018: Oxford & Manchester, UK and Atlanta, GA. Cytox, a precision medicine testing company ...

Read More >